Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials

Jan Beyer-Westendorf*, Anthonie W. A. Lensing, Roopen Arya, Henri Bounameaux, Alexander T. Cohen, Philip S. Wells, Saskia Middeldorp, Peter Verhamme, Rodney Hughes, Nils Kucher, Akos F. Pap, Mila Trajanovic, Martin H. Prins, Paolo Prandoni, Jeffrey I. Weitz

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)29-37
Number of pages9
JournalThrombosis Research
Volume149
DOIs
Publication statusPublished - Jan 2017

Keywords

  • anticoagulation
  • rivaroxaban
  • apixaban
  • venous thromboembolism
  • ACUTE VENOUS THROMBOEMBOLISM
  • RANDOMIZED CONTROLLED-TRIALS
  • VITAMIN-K ANTAGONISTS
  • ORAL ANTICOAGULANTS
  • DOUBLE-BLIND
  • OPEN-LABEL
  • METAANALYSIS
  • CANCER
  • RIVAROXABAN
  • DABIGATRAN

Cite this

Beyer-Westendorf, J., Lensing, A. W. A., Arya, R., Bounameaux, H., Cohen, A. T., Wells, P. S., Middeldorp, S., Verhamme, P., Hughes, R., Kucher, N., Pap, A. F., Trajanovic, M., Prins, M. H., Prandoni, P., & Weitz, J. I. (2017). Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. Thrombosis Research, 149, 29-37. https://doi.org/10.1016/j.thromres.2016.11.014